Richard A. Koup

Richard A. Koup

Auto-generated profile, based on publicly available information

Richard A. Koup

Tissue Analysis Core, Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2006 in Blood
Verified
Journal Article
Open access
PDF file
MBMichael R. Betts
Michael R. Betts
MNMartha C. Nason
Martha C. Nason
SWSadie M. West
Sadie M. West
SRStephen C. De Rosa
Stephen C. De Rosa
SMStephen A. Migueles
Stephen A. Migueles
RKRichard A. Koup
Richard A. Koup
Establishing a CD8+ T cell–mediated immune correlate of protection in HIV disease is crucial to the development of vaccines designed to generate cell

7 January 2022 in Science
Verified
Journal Article
Open access
PGPeter B. Gilbert
Peter B. Gilbert
DMDavid C. Montefiori
David C. Montefiori
AMAdrian B. McDermott
Adrian B. McDermott
YFYouyi Fong
Youyi Fong
DBDavid Benkeser
David Benkeser
UTUnited States Government (USG)/CoVPN Biostatistics Team
United States Government (USG)/CoVPN Biostatistics Team
Antibody levels predict vaccine efficacy: Symptomatic COVID-19 infection can be prevented by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. A “correlate of protection” is a molecular biomarker to measure how much immunity is needed to fight infection and is key for successful global immunization programs. Gilbert et al . determined that antibodies are the correlate of protection in vaccinated individuals enrolled in the Moderna COVE phase 3 clinical trial (see the Perspective by Openshaw). By measuring binding and neutralizing antibodies against the viral spike protein, the authors found that the levels of both antibodies correlated with the degree of vaccine efficacy. The higher the antibody level, the greater the protection afforded by the messenger RNA (mRNA) vaccine. Antibody levels that predict mRNA vaccine efficacy can therefore be used to guide vaccine regimen modifications and support regulatory approvals for a broader spectrum of the population. —PNK

5 September 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
CPConstantinos Petrovas
Constantinos Petrovas
JCJoseph P. Casazza
Joseph P. Casazza
JBJason M. Brenchley
Jason M. Brenchley
DPDavid A. Price
David A. Price
EGEmma Gostick
Emma Gostick
RKRichard A. Koup
Richard A. Koup
Here, we report on the expression of programmed death (PD)-1 on human virus-specific CD8+ T cells and the effect of manipulating signaling through PD-1 on the survival, proliferation, and cytokine function of these cells. PD-1 expression was found to be low on naive CD8+ T cells and increased on memory CD8+ T cells according to antigen specificity. Memory CD8+ T cells specific for poorly controlled chronic persistent virus (HIV) more frequently expressed PD-1 than memory CD8+ T cells specific for well-controlled persistent virus (cytomegalovirus) or acute (vaccinia) viruses. PD-1 expression was independent of maturational markers on memory CD8+ T cells and was not directly associated with an inability to produce cytokines. Importantly, the level of PD-1 surface expression was the primary determinant of apoptosis sensitivity of virus-specific CD8+ T cells. Manipulation of PD-1 led to changes in the ability of the cells to survive and expand, which, over several days, affected the number of cells expressing cytokines. Therefore, PD-1 is a major regulator of apoptosis that can impact the frequency of antiviral T cells in chronic infections such as HIV, and could be manipulated to improve HIV-specific CD8+ T cell numbers, but possibly not all functions in vivo.

1 February 2009 in Annual Review of Medicine
Verified
Journal Article
Closed access
DDDaniel C. Douek
Daniel C. Douek
MRMario Roederer
Mario Roederer
RKRichard A. Koup
Richard A. Koup
There is an intense interplay between HIV and the immune system, and the literature is replete with studies describing various immunological phenomena associated with HIV infection. Many of these phenomena seem too broad in scope to be attributable either to HIV-infected cells or to the HIV-specific immune response. Recently, a more fundamental understanding of how HIV affects various T cells and T cell compartments has emerged. This review covers the role of immune activation in HIV immunopathogenesis, how that activation could be mediated directly by HIV replicating within and damaging the gut mucosal barrier, how HIV affects multiple T cell functions and phenotypes, and how chronic HIV replication induces immune modulatory pathways to negatively regulate certain functions in HIV-specific T cells.

29 May 2007 in Journal of Experimental Medicine
Verified
Journal Article
Open access
MPMelissa L. Precopio
Melissa L. Precopio
MBMichael R. Betts
Michael R. Betts
JPJanie Parrino
Janie Parrino
DPDavid A. Price
David A. Price
EGEmma Gostick
Emma Gostick
RKRichard A. Koup
Richard A. Koup
Vaccinia virus immunization provides lifelong protection against smallpox, but the mechanisms of this exquisite protection are unknown. We used polychromatic flow cytometry to characterize the functional and phenotypic profile of CD8+ T cells induced by vaccinia virus immunization in a comparative vaccine trial of modified vaccinia virus Ankara (MVA) versus Dryvax immunization in which protection was assessed against subsequent Dryvax challenge. Vaccinia virus–specific CD8+ T cells induced by both MVA and Dryvax were highly polyfunctional; they degranulated and produced interferon γ, interleukin 2, macrophage inflammatory protein 1β, and tumor necrosis factor α after antigenic stimulation. Responding CD8+ T cells exhibited an unusual phenotype (CD45RO−CD27intermediate). The unique phenotype and high degree of polyfunctionality induced by vaccinia virus also extended to inserted HIV gene products of recombinant NYVAC. This quality of the CD8+ T cell response may be at least partially responsible for the profound efficacy of these vaccines in protection against smallpox and serves as a benchmark against which other vaccines can be evaluated.

1 February 2004 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
JBJason M. Brenchley
Jason M. Brenchley
BHBrenna J. Hill
Brenna J. Hill
DADavid R. Ambrozak
David R. Ambrozak
DPDavid A. Price
David A. Price
FGFrancisco J. Guenaga
Francisco J. Guenaga
RKRichard A. Koup
Richard A. Koup
Identification of T-cell subsets that are infected in vivo is essential to understanding the pathogenesis of human immunodeficiency virus (HIV) disease; however, this goal has been beset with technical challenges. Here, we used polychromatic flow cytometry to sort multiple T-cell subsets to 99.8% purity, followed by quantitative PCR to quantify HIVgagDNA directly ex vivo. We show that resting memory CD4+T cells are the predominantly infected cells but that terminally differentiated memory CD4+T cells contain 10-fold fewer copies of HIV DNA. Memory CD8+T cells can also be infected upon upregulation of CD4; however, this is infrequent and HIV-specific CD8+T cells are not infected preferentially. Naïve CD4+T-cell infection is rare and principally confined to those peripheral T cells that have proliferated. Furthermore, the virus is essentially absent from naïve CD8+T cells, suggesting that the thymus is not a major source of HIV-infected T cells in the periphery. These data illuminate the underlying mechanisms that distort T-cell homeostasis in HIV infection.